Salarius Pharmaceuticals, Inc. (SLRX)
NASDAQ: SLRX · Real-Time Price · USD
0.7190
+0.0600 (9.10%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Salarius Pharmaceuticals Employees
Salarius Pharmaceuticals had 2 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
2
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,787,889
Market Cap
1.26M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
SLRX News
- 7 days ago - Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board - GlobeNewsWire
- 4 weeks ago - Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers - GlobeNewsWire
- 3 months ago - Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge - Benzinga
- 11 months ago - Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split - GlobeNewsWire
- 1 year ago - Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 1 year ago - Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment - GlobeNewsWire
- 1 year ago - Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program - GlobeNewsWire